Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Inclusion criteria

• ✓. Patient who is able to provide written informed consent (as required by Institutional Review Board \[IRB\]) prior to the initiation of any protocol-required procedures.
• ✓. Must be willing to be hospitalized for the duration of the inpatient period of the study.
• ✓. Have stable living environment when not in a hospital.
• ✓. Male and female patients 18 to 55 years of age inclusive at the time of informed consent with a diagnosis of schizophrenia as defined by DSM-5 criteria and confirmed by the MINI 7.0.2 .
• ✓. Body mass index (BMI) must be ≥18 and ≤40 kg/m2.
• ✓. Patient who experiencing an acute exacerbation of psychotic symptoms, AND the patient requires hospitalization OR if already an inpatient at Screening, has been hospitalized for onset \< 2 weeks for the current exacerbation.
• ✓. Patients who are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by meeting ALL of the following criteria at the Screening and Baseline visits:
• ✓. Have received previous antipsychotic treatment (dose and duration as per the label) and who showed a previous good response to such antipsychotic treatment (other than clozapine) in the last 12 months, according to the Investigator's opinion.